The Future of Cancer Research
Consensus among stakeholders is needed to find solutions to critical questions regarding the future of clinical cancer research. Throughout this day-long conference, panelists sought to address this challenge, discussing pressing scientific and regulatory challenges and opportunities for progress in innovations in cancer therapy. The first three panels discussed options for clinical data standards, alternative methods for demonstrating the efficacy of promising therapies, and approaches to the joint development of cancer drugs and diagnostic tests. The final panel explored the vision for the future of FDA – looking at how FDA can guide innovation and respond to the challenges of a quickly advancing field.
Featured panelists included Dr. Mark McClellan, Dr. David Kessler, Dr. Ellen Sigal, Dr. Janet Woodcock, and others representing the industry, advocacy, regulatory, and academic and government research communities. NCI Director Dr. John Niederhuber made opening remarks, and FDA Commissioner Dr. Andrew von Eschenbach delivered a luncheon keynote address.
The event was convened by the Engelberg Center for Health Care Reform at Brookings in conjunction with the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and Friends of Cancer Research hosted the Conference on Clinical Cancer Research.